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ABSTRACT 
Addressing the global burden of cancer, understanding its diverse biology, and promoting 
appropriate prevention and treatment strategies around the world has become a priority for 
the United Nations and International Atomic Energy Agency (IAEA), the World Health 
Organisation, and International Agency for Research on Cancer (IARC). The IAEA 
sponsored an international prospective cohort study to better understand biology, treatment 
response, and outcomes of diffuse large B-cell lymphoma (DLBCL) in low and middle-income 
countries across five UN-defined geographical regions. We report an analysis of biological 
variation in DLBCL across seven ethnic and environmentally diverse populations. In this 
cohort of 136 patients treated to a common protocol, we demonstrate significant biological 
differences between countries, characterised by a validated prognostic gene expression 
score (p<0.0001), but International Prognostic Index-adjusted survivals in all participating 
countries were similar. We conclude that DLBCL treatment outcomes in these populations 
can be benchmarked to international standards, despite biological heterogeneity. 
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INTRODUCTION 
Cancer centres around the world may wish to compare their results against published studies 
from high-income Caucasian populations. Attempts to produce similar remission and survival 
rates across diverse populations may not be achievable if disease biology differs in low or 
middle income countries. Biological variation may arise from ethnic diversity which may 
influence host response, or the physical or microbiological environment which may influence 
causation and disease biology. 
The International Atomic Energy Agency (IAEA) sponsored a prospective cohort study of 
diffuse large B-cell lymphoma (DLBCL) in countries from five United Nations defined 
geographical regions [1]. The study had two pre-defined aims: the first to investigate whether 
there was inter-country heterogeneity in speed of response, as assessed by positron 
emission tomography (PET), as a predictor of future survival; the second, to explore whether 
the biological characteristics of DLBCL differ and influence outcomes between countries. 
Analysis of the 327 patients with complete data for the PET monitoring component of the 
study has recently been reported [2]. We report here the analysis of between country 
biological heterogeneity and relate this to survival. 
MATERIALS and METHODS 
Patients and Treatment 
The protocol was developed by the IAEA wth all international collaborators between 2006-
2008. Adults >16y with newly diagnosed DLBCL were recruited at major cancer centres in 
seven countries in Western Europe, Central Asia, South Asia, South East Asia and South 
America, during 2008-2012. Treatment was with a common chemotherapy protocol: 
Cyclophosphamide, Adriamycin, Vincristine, Prednisolone with Rituximab (R-CHOP), 
delivered at 21 day intervals. Omission of rituximab was permitted in a small number of 
patients who might otherwise have been excluded for financial reasons [2].  
Treatment Response Assessment 
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Treatment response was based on international criteria [3]. To accurately adjust outcomes 
for IPI, pre-treatment staging was based on CT and PET imaging in all centres, and final 
response status was based on central reading of all end-treatment PET scans at a final 
investigator meeting, as previously described [2]. Event-free survival (EFS) at the validated 
time-point of 24 months was used as the comparative outcome measure [4]. We do not 
report overall survival, as this is strongly influenced by the variable approaches between 
countries to salvaging those who relapse. The common study protocol and assessment of 
outcomes has been described in greater detail elsewhere [2]. 
Measure of Biological Diversity 
As the measure of biological variation, we used the 6-gene-expression score for predicting 
survival of patients with DLBCL, first published in 2004 by Losses et al. [5]. This ‘mortality 
score’ is derived from expression levels of 6 informative genes (3 predictive of better survival 
LM02, BCL6, FN1, and 3 of worse survival CCND2, BCL2, SCYA3) which together stratified 
patients into low, medium and high risk groups. When considered as a continuous variable 
the 6-gene score predicted overall survival for patients treated with CHOP [5] and both 
overall and progression free survival in a larger cohort treated with R-CHOP [6].  
Molecular Methods 
RNA was extracted from formalin-fixed diagnostic tissue [6] and sent to a central laboratory 
(Biotechnology Institute, Ankara University, Turkey) for analysis. Analyses were all 
performed by authors NT and HO. 
RNA, 1000ng, was used to synthesize cDNA using ABI High-Capacity cDNA Reverse 
Transcription in 100l, and 2l (20ng/l) cDNA used for each QPCR reaction. Standard 
curves were prepared from plasmids containing the cloned target genes. Taqman QPCR 
assays of the 6 genes plus ABL were conducted on a Light Cycler 480 platform (Roche, 
Germany) using standard methodology. Expression ratios were calculated based on delta 
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delta Ct26 R=2(–CT). The 6-gene score was calculated as originally described [4,5] and 
included in analyses as a continuous variable. 
Statistical Methods 
The analysis used a Cox model to stratify by country and initially included the 6-gene score, 
International Prognostic Index (IPI) and rituximab exposure as relevant predictive variables. 
However, as this model did not converge sufficiently due to few events per parameter, the 
final analysis investigated each variable separately in a Cox model stratified by country. 
Research Governance 
The study was approved by the relevant Research Ethics Committee, or Institutional Review 
Board in each participating centre. All patients were recruited into the study after gaining 
informed consent. Biological material and data were shared between countries only identified 
by a study code number and with all personal identifiers removed. 
Role of the Funding Source 
The IAEA provided funding which made the study possible, but had no role in the design, 
analysis or interpretation of the data, nor the decision to publish. 
RESULTS 
Complete molecular and clinical data were available for 136 patients. Sixty one were from 
high-income countries (Chile, Hungary, South Korea), 40 from upper-middle income 
countries (Thailand, Turkey), 35 from lower-middle income countries (India, Philippines) 
(table 1). There was good compliance with the common treatment protocol and 114/136 
(84%) of all patients received rituximab (table 1).  
At a median follow up of 2y and 6 months, 2y EFS for the 136 patients was 74% (95% 
Confidence Interval 65-84%), similar to the 2y EFS recently reported from a large UK 
R-CHOP trial, 75% (71-78%) [7]. There was moderate variation between individual countries, 
from 85% 2y EFS in Chile to 56% in Turkey (figure 1)  
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The distribution of individual gene expression varied significantly between countries 
(P<0.0001) (figure 2a). When combined into the 6-gene score there similarly was significant 
between-country heterogeneity (P<0.0001) (figure 2b). The distribution of 6-gene scores 
within and between countries did not suggest any association with geographical region or 
country economic status. 
Our interest was to investigate whether the highly significant between-country variation in the 
6-gene prognostic score might explain the observed differences in event-free survivals. 
Multivariate analysis found only the IPI to be a significant predictor of outcome (P=0.009), 
whereas neither the 6-gene score (P=0.21), nor variation in use of rituximab between 
countries (P=0.08) were significant explanatory factors. 
To gain further insight into how adjustment for IPI or 6-gene score might individually 
influence the relative 2y EFS between countries, Kaplan-Meier plots were generated from the 
Cox analyses, including country as a co-variate rather than stratifying variable. Within each 
country individual patient outcomes were normalised to remove the positive or negative 
influence of either the 6-gene score or IPI on EFS, then plotted as an adjusted survival curve. 
Composite figures displaying these modelled survival curves by country, without adjustment, 
adjusted for IPI or adjusted for 6-gene score are shown (figure 3)  
Compared to the unadjusted 2y EFS (figure 3a), adjustment for IPI (figure 3b) brings the 
survival curves closer together, with little difference at 2 years between Chile, Hungary, S. 
Korea and Thailand. The survival curves for India, Philippines and Turkey form a second 
cluster with comparatively inferior 2y EFS. This figure reveals Turkey to have markedly 
improved 2y survival after adjustment for IPI, reflecting the high proportion of high IPI cases. 
India and Philippines have 2y EFS approximately 15% lower than Chile, Hungary and 
S.Korea, reflecting the lower use of rituximab (table 1). By contrast, adjustment for the 
6-gene score (figure 3c) failed to bring the individual country survival curves closer together, 
thus demonstrating that variation in disease biology made no perceptible contribution to 
event-free survival differences between countries.  
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DISCUSSION 
The goal for oncologists in emerging economies is to achieve cancer outcomes comparable 
to the developed world [8]. The effects of late presentations with advanced disease, or 
reduced resources for expensive treatments are recognised challenges that may confound 
direct comparisons. The possible influence of variable biology across continents, even within 
the single histological entity of this commonest of lymphomas is currently unknown. 
Global variation in the prevalence of different NHL sub-types is well recognised [8]. The 
effect of environmental factors on DLBCL incidence, including levels of UV irradiation and 
infections have recently been reviewed and EBV associated with DLBCL is recognised as 
conferring poorer prognosis [10-13]. More recently, different inflammatory gene signatures 
within DLBCL tissue has been reported between Scandinavian and Egyptian cohorts [14].  
When designing this biological component of the IAEA DLBCL study, an important 
consideration was selection of biological markers with proven relationship to survival, and 
which could be assayed using RNA from fixed tissue in a central laboratory. The 6-gene 
prognostic algorithm described by Lossos [5] had recently been published and had the merit 
of using standard methodology. Though initially devised for individual patient risk 
stratification, we used it as a global index of biological variation.  
Though of lesser prognostic value in patients treated with immunochemotherapy [15], the 
intention had been to also include classification of cases as ABC or GCB subtypes. However 
this proved impracticable due lack of resources for the necessary establishment of between 
centre consistency in immuno-histocytochemistry, or central processing and reporting of all 
diagnostic biopsy sections [16]. 
The more recent 6-gene score study by Malumbres and colleagues [6] examined its 
relationship to outcomes of 132 patients treated with R-CHOP in 3 centres from North 
America, Canada and Spain. The authors did not report any between-centre heterogeneity in 
gene scores, but found in this population that, as in ours, IPI was the most significant 
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predictor of individual progression-free survival. However, the cohort was more 
homogeneous than ours in terms of ethnicity and socio-economic background and, in 
contrast to ours, demonstrated identical unadjusted 2y survival at the 3 centres.   
No study, to our knowledge, has documented biological heterogeneity across a wide range of 
socio-economic environments or ethnically diverse populations, and related this to outcomes.  
Understanding the influence of variable disease characteristics between countries is an 
essential step in the global effort to improve lymphoma outcomes. Our study confirms the 
existence of significant biological heterogeneity between the populations investigated. It is to 
be hoped that in the future more detailed analysis of genetic variation may be exploited to 
give insights into the causation of this common lymphoma. 
For clinicians internationally, we have demonstrated that when adjusted for the International 
Prognostic Index, event-free survivals for diffuse large B-cell lymphoma are comparable 
across seven socio-economic and ethnically diverse countries, despite significant differences 
in a validated prognostic gene-expression score. Where treatment includes rituximab, 
survivals are similar to recent European cohorts.  
These observations provide necessary evidence that leading cancer centres around the 
world can benchmark their outcomes to those in high-income Western populations. 
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TABLE 1 
 
Patient characteristic and 2y event free survival by country 
 
 
  
 Chile Hungary India Philippines South 
Korea 
Thailand Turkey All cases 
Patients (n) 27 27 22 13 7 24 16 136 
Age in years 
(median) 
61  56  52  51  48  56  54  55  
IPI 0–1  
    2 
    3 
 4–5 
12 (44%) 
3 (11%) 
6 (22%) 
6 (22%) 
18 (67%) 
2 (7%) 
5 (19%) 
2 (7%) 
10 (45%) 
10 (45%) 
2 (9%) 
0 (0%) 
4 (31%) 
3 (23%) 
4 (31%) 
2 (15%) 
1 (14%) 
3 (43%) 
2 (29%) 
1 (14%) 
9 (37%) 
6 (25%) 
6 (25%) 
3 (13%) 
3 (19%) 
5 (31%) 
3 (19%) 
5 (31%) 
42% 
24% 
21% 
14% 
Treatment 
+ Rituximab 
26 (96%) 27 (100%) 14 (64%) 8 (62%) 7 (100%) 16 (67%) 16 (100%) 84% 
 
2y EFS % 
 
85%  80%  67%  66%  71%  74%  56%  73%  
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FIGURE LEGENDS 
Figure 1 
Composite of Kaplan-Meier plots showing event-free survival (EFS) for each country. 
 
Figure 2 
Heterogeneity of prognostic gene expression between countries. 
A) Expression of the 6 individual prognostic genes for each study patient, by country.  
 
B) Individual 6-gene scores, by country. Boxes represent median and inter-quartile range. 
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Figure 3 
Kaplan-Meier EFS risk estimates for each country, generated from the Cox analysis. 
A) Unadjusted survival risk estimates 
 
B) Risk estimates, normalised to adjust for IPI. 
    (Note: Survival estimates for Hungary and S. Korea are superimposed in this figure) 
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C) Risk estimates, normalised to adjust for 6-gene scores. 
 
 
